Research Article

Characteristics of Symptomatic and Asymptomatic Patients With COVID-19 and Seroprevalence of anti-SARS-CoV-2 Antibodies in Zavidovići, Bosnia and Herzegovina

Senad Huseinagić
Institute for Health and Food Safety, Bosnia and Herzegovina
Selvedina Sarajlić-Spahić
Institute for Health and Food Safety, Bosnia and Herzegovina
Fatima Bašić
Institute for Health and Food Safety, Bosnia and Herzegovina
Jasmin Durmišević
Institute for Health and Food Safety, Bosnia and Herzegovina
Amir Ibrahimagić
Institute for Health and Food Safety Zenica, Bosnia and Herzegovina
* Corresponding author
DOI icon 10.24018/ejmed.2022.4.1.1213

Read Counter
349

Downloads
381

Citations

Share

Article Sidebar

Submitted 2022-01-18
Published 2022-02-10

Read counter = 349 times

Table of Contents

Article Main Content

Human coronaviruses are agent which cause respiratory illnesses and have been described to be continously emerging. Seroprevalence of IgM/IgG antibodies was determined by lateral flow immunoassay. Study were include data on participants experience of COVID-19 symptoms during the pandemic (including symptoms and health status). Among 443 serum samples for detection seroprevalence, 186 (42.0%) were seropositive on specific antibodies (IgM/IgG) or participants who had COVID-19 with or without symptoms. Of the seropositive the age group 25-50 years old had the highest percentage (32.8%) followed by 51-64 years (30.6%). Ninety seropositive patients (out of 186; 48.4%) were detected with the specific symptoms. The most frequently symptoms were fever (n=54, out of 90; 60.0%), muscle pain (46.7%), dry cough and loss of smell (36.7%) and others. More than one symptoms were detected in 59 cases (65.6%). The most common comorbidities were diabetes mellitus (n=12, out of 186; 6.5%), than hypertension (nine; 4.8%) and heart diseases (seven; 3.8%). More than half of seropositive were asymptomatic (n=96, out of 186; 51.6%). Note: In period March 2020 - June 2021, among 3323 samples, 804 (24.2%) were positive on SARS-CoV-19 with RT-PCR. The results showed that 394 (out of 804; 49.0%) positive samples were collected from female and 410 (51.0%) from male. The most prevalent of SARS-CoV-19 viruses were detected in > 65 years old (n=267, out of 804; 33.2%). Further research on the contribution of symptomatic or asymptomatic individuals to the community spread of COVID-19 is essential for effective control of the pandemic spread of SARS-CoV-2.

Keywords: Coronavirus, comorbidity, seroprevalence, symptoms

References

  1. WHO. Coronavirus Disease 2019 (COVID-19) Situation Report - 61. [Internet] [cited 2020 March 20] Available from at: http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200321 -sitrep-61-covid-19.pdf?sfvrsn=6aa18912_2
     Google Scholar
  2. Memish ZA, Cotten M, Meyer B, Watson SJ, Alsahafi AJ, Al Rabeeah AA, et al. Human infection with MERS coronavirus after exposure to infected Camels, Saudi Arabia, 2013. Emerg Infect Dis. 2014; 20(6): 1012–1015.
    DOI  |   Google Scholar
  3. Song JY, Yun JG, Noh JY, Cheong HJ, Kim WJ. Covid-19 in South Korea - Challenges of subclinical manifestations. N Engl. J Med. 2020; 382; 1858-1859.
    DOI  |   Google Scholar
  4. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan. Euro Surveill. 2020; 25: 2000180.
    DOI  |   Google Scholar
  5. Nishiura H, Kobayashi T, Suzuki A, Jung S, Hayashi K, Kinoshita R, et al. Estimation of the asymtpomatic ration of novel coronavirus infections (COVID-19). Int J Infectious Dis. 2020; 94: 154-155.
    DOI  |   Google Scholar
  6. Li Y, Shi J, Xia J, Duan J, Chen L, Yu X, et al. Asymptomatic and symptomatic patients with non-severe coronavirus disease (COVID-19) have similar clinical features and virological courses: A retrospective single center study. Fron Microbiol. 2020; 11; 1570.
    DOI  |   Google Scholar
  7. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Eng J Med. 2020; 382: 1177-1179.
    DOI  |   Google Scholar
  8. Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: comparison with SARS and MERS. Rev Med Virol.2020; 30:e2107.
    DOI  |   Google Scholar
  9. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic and symptomatic patients. Clin Microbiol Infect. 2020; 26: 948.e1-948.e3.
    DOI  |   Google Scholar
  10. Al Qahtani M, Al Ali S, AbdulRahman A, Alsayyad AS, Otoom S, Atkin SL. The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects. Int J Infect Dis. 2021; 102: 285-288.
    DOI  |   Google Scholar
  11. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2–specific antibodies among adults in Los Angeles county, California, on April 10-11, 2020. JAMA. 2020; 323(23): 2425–2427.
    DOI  |   Google Scholar
  12. Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. medRxiv. 2020.
    DOI  |   Google Scholar
  13. Uyoga S, Adetifa IM, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science. 2021; 371(6524): 79-82.
    DOI  |   Google Scholar
  14. Balou HA, Kalurazi TY, Joukar F, Hassanipour S, Shenagari M, Khoshsorour M, et al. High seroprevalence of SARS-CoV-2 (COVID-19)-specific antibodies among heatlhcare workers: a cross-sectional study in Guilan, Iran. Journal of Environmental and Public Health. 2021.
    DOI  |   Google Scholar
  15. Shakiba M, Nazari SSH, Mehrabian F, Rezvani SM, Ghasempour Z, Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province. Emerging Infectious Diseases. 2020; 27: 636-638.
    DOI  |   Google Scholar
  16. Mulabbi EN, Tweyongyere R, Mangen FW, Mworozi E, Koehlerb J, Kibuuka H, et al. Seroprevalence of human coronaviruses among patients visiting hospital-based sentinel sites in Uganda. BMC Infectious Diseases. 2021; 21: 585.
    DOI  |   Google Scholar
  17. Rostami A, Sepidarkish M, Fazlzadeh A, Mokdad AH, Sattarnezhad A, Esfandyari S, et al. Update on SARS-CoV-2 seroprevalence: regional and worldwide. Clin Microbiol Infect. 2021; 27: 1762-1771.
    DOI  |   Google Scholar
  18. Jung CY, Park H, Kim DW, Choi YJ, Kim SW. Clinical characteristics of asymptomatic patients with COVID-19: A nationwide cohort study in South Korea. Int J Infectious Dis. 2020; 99: 266-268.
    DOI  |   Google Scholar
  19. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARSCoV-2 in the Icelandic population. N Engl J Med. 2020; 382(24): 2302-2315.
    DOI  |   Google Scholar
  20. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Vecchio CD, et al. Suppression of COVID-19 outbreak in the municipality of Vo, Italy. medRxiv. 2020.
    DOI  |   Google Scholar
  21. IU, ISDH release preliminary findings about impact of COVID-19 in Indiana. Indiana University. [Internet] [cited 2020 May 13] Accessed from: https://news.iu.edu/stories/2020/05/iupui/releases/13-preliminary-findings -impact-covid-19-indiana-coronavirus.html
     Google Scholar
  22. Zeng H, Ma Y, Zhou Z, Liu W, Huang P, Jiang M, et al. Spectrum and clinical characteristics of symptomatic and asymptomatic coronavirus disease 2019 (COVID-19) with and without pneumonia. Front Med. 2021; 8: 645651.
    DOI  |   Google Scholar
  23. Gostić K, Gomez AC, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. Elife. 9: e55570.
    DOI  |   Google Scholar
  24. Aziz NA, Corman VM, Echterhoff AKC, Richter A, Schmandke A, Schmidt ML, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany. medRxiv. 2020.
    DOI  |   Google Scholar
  25. Iwuji K, Islam E, Berdine G, Nugent K, Test V, Tijerina A. Prevalence of coronavirus antibody among first responders in Lubbock, Texas. J Prim Care Community Health. 2020; 11: 2150132720971390.
    DOI  |   Google Scholar
  26. Ladage D, Höglinger Y, Ladage D, Adler C, Yalcin I, Braun RJ. SARS-CoV-2 antibody prevalence and symptoms in a local Austrian population. Front. Med. 2021.
    DOI  |   Google Scholar
  27. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020; 396(10247): 313–319.
    DOI  |   Google Scholar
  28. Signorelli C, Scognamiglio T, Odone A. COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Biomedica: Atenei Parmensis. 2020; 91: 175-179.
     Google Scholar
  29. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Shiadeh MN, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021; 27(3): 331–340.
    DOI  |   Google Scholar
  30. Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jimenez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020; 11: 3500.
    DOI  |   Google Scholar
  31. Song SK, Lee DH, Nam JH, Kim KT, Do JS, Kang DW, et al. IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea. J Korean Med Sci. 2020; 35(29): e269.
    DOI  |   Google Scholar
  32. Streeck H, Schulte B, Kuemmerer B, Richter E, Höller T, Fuhrmann C, et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nature Communications. 2020; 11: 5829.
    DOI  |   Google Scholar